Patents by Inventor John Raelson

John Raelson has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Genomic markers for prediction of long-term response to 2 years of growth hormone (GH) therapy
    Patent number: 9206480
    Abstract: The present invention relates to the use of genetic markers to identify the response to growth hormone treatment in Growth Hormone Deficiency (GHD) or Turner Syndrome (TS) patients as well as a method of treating GHD or TS patients and kits for genotyping.
    Type: Grant
    Filed: May 10, 2012
    Date of Patent: December 8, 2015
    Assignee: ARES TRADING S.A.
    Inventors: Pascal Croteau, Benoit Destenaves, Clement Olivier, John Raelson
  • Genomic markers for prediction of long-term response to growth hormone (GH) therapy
    Patent number: 9175347
    Abstract: The present invention relates to the use of genetic markers to identify the response to growth hormone treatment in Growth Hormone Deficiency (GHD) or Turner Syndrome (TS) patients as well as a method of treating GHD or TS patients and kits for genotyping.
    Type: Grant
    Filed: August 31, 2011
    Date of Patent: November 3, 2015
    Assignee: MERCK SERONO SA
    Inventors: Pascal Croteau, John Raelson, Jerome Wojcik, Benoît Destenaves, Clement Olivier, Sonia Schnieper-Samec
  • GENOMIC MARKERS FOR PREDICTION OF LONG-TERM RESPONSE TO 2 YEARS OF GROWTH HORMONE (GH) THERAPY
    Publication number: 20140088012
    Abstract: The present invention relates to the use of genetic markers to identify the response to growth hormone treatment in Growth Hormone Deficiency (GHD) or Turner Syndrome (TS) patients as well as a method of treating GHD or TS patients and kits for genotyping.
    Type: Application
    Filed: May 10, 2012
    Publication date: March 27, 2014
    Applicant: ARES TRADING S.A.
    Inventors: Pascal Croteau, Benoit Destenaves, Clement Olivier, John Raelson
  • GENOMIC MARKERS FOR PREDICTION OF LONG-TERM RESPONSE TO GROWTH HORMONE (GH) THERAPY
    Publication number: 20130157952
    Abstract: The present invention relates to the use of genetic markers to identify the response to growth hormone treatment in Growth Hormone Deficiency (GHD) or Turner Syndrome (TS) patients as well as a method of treating GHD or TS patients and kits for genotyping.
    Type: Application
    Filed: August 31, 2011
    Publication date: June 20, 2013
    Applicant: MERCK SERONO S.A.
    Inventors: Pascal Croteau, John Raelson, Jerome Wojcik, Benoît Destenaves, Clement Olivier, Sonia Schnieper-Samec
  • METHODS AND AGENTS FOR EVALUATING INFLAMMATORY BOWEL DISEASE, AND TARGETS FOR TREATMENT
    Publication number: 20100167285
    Abstract: The invention provides methods for evaluating irritable bowel disease (IBD), including Crohn Disease and Ulcerative Colitis, methods for determining a patient's susceptibility to developing an IBD, and methods for determining a patient's IBD genotype. The invention includes methods, polynucleotides, polypeptides, and antibodies relating to disclosed variants of, and polymorphisms in, the nel-like 1 precursor (NELL1), as well as the 5p13.1 locus, and other genes disclosed herein to be associated with IBD. Thus, the invention provides diagnostic and/or therapeutic targets for IBD, as well as diagnostic and therapeutic agents for IBD.
    Type: Application
    Filed: March 26, 2008
    Publication date: July 1, 2010
    Inventors: Stefan Schreiber, Philip Rosenstiel, Andreas Ruether, Andre Franke, John Raelson, Randall D. Little, Tim Keith, Helene Fournier